BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8907134)

  • 1. Safety of levosimendan and other calcium sensitizers.
    Lehtonen L; Mills-Owens P; Akkila J
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S70-6. PubMed ID: 8907134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B; Prasad AS; Economides C; Singh BN
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A promising new inotrope: levosimendan.
    Fotbolcu H; Duman D
    Anadolu Kardiyol Derg; 2010 Apr; 10(2):176-82. PubMed ID: 20382619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan: implications for clinicians.
    McBride BF; White CM
    J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 9. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies.
    Lilleberg J; Ylönen V; Lehtonen L; Toivonen L
    Scand Cardiovasc J; 2004 May; 38(2):80-4. PubMed ID: 15204232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.
    Husebye T; Eritsland J; Müller C; Sandvik L; Arnesen H; Seljeflot I; Mangschau A; Bjørnerheim R; Andersen GØ
    Eur J Heart Fail; 2013 May; 15(5):565-72. PubMed ID: 23288914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan: current status and future prospects.
    Archan S; Toller W
    Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan compared with dobutamine in low output patients.
    Nieminen MS
    Minerva Anestesiol; 2003 Apr; 69(4):258-63. PubMed ID: 12766717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction.
    Lilleberg J; Sundberg S; Nieminen MS
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S63-9. PubMed ID: 8907133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure.
    Sandell EP; Hayha M; Antila S; Heikkinen P; Ottoila P; Lehtonen LA; Pentikainen PJ
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S57-62. PubMed ID: 8907132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair.
    Ponschab M; Hochmair N; Ghazwinian N; Mueller T; Plöchl W
    Eur J Anaesthesiol; 2008 Aug; 25(8):627-33. PubMed ID: 18405408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
    De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
    Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical trials with levosimendan.
    Mebazaa A; Barraud D; Welschbillig S
    Am J Cardiol; 2005 Sep; 96(6A):74G-9G. PubMed ID: 16181826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.